Evidence map›Paper›PMID 37069607›Full record

ArticleJournal of translational medicine2023

The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study.

Ki-Kwang Oh, Sang-Jun Yoon, Su-Been Lee, Sang Youn Lee, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Sung-Min Won, Jin-Ju Jeong, Dong Joon Kim and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ki-Kwang OhInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Sang-Jun YoonInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Su-Been LeeInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Sang Youn LeeInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Haripriya GuptaInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Raja GanesanInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Satya Priya SharmaInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Sung-Min WonInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Jin-Ju JeongInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Dong Joon KimInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
Ki-Tae SukInstitute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea. ktsuk@hallym.ac.kr.
Hallym University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is a serious public health issue globally, currently, the treatment of NAFLD lies still in the labyrinth. In the inchoate stage, the combinatorial application of food regimen and favorable gut microbiota (GM) are considered as an alternative therapeutic. Accordingly, we integrated secondary metabolites (SMs) from GM and Avena sativa (AS) known as potent dietary grain to identify the combinatorial efficacy through network pharmacology.

methodsWe browsed the SMs of AS via Natural Product Activity & Species Source (NPASS) database and SMs of GM were retrieved by gutMGene database. Then, specific intersecting targets were identified from targets related to SMs of AS and GM. The final targets were selected on NAFLD-related targets, which was considered as crucial targets. The protein-protein interaction (PPI) networks and bubble chart analysis to identify a hub target and a key signaling pathway were conducted, respectively. In parallel, we analyzed the relationship of GM or AS─a key signaling pathway─targets─SMs (GASTM) by merging the five components via RPackage. We identified key SMs on a key signaling pathway via molecular docking assay (MDA). Finally, the identified key SMs were verified the physicochemical properties and toxicity in silico platform.

resultsThe final 16 targets were regarded as critical proteins against NAFLD, and Vascular Endothelial Growth Factor A (VEGFA) was a key target in PPI network analysis. The PI3K-Akt signaling pathway was the uppermost mechanism associated with VEGFA as an antagonistic mode. GASTM networks represented 122 nodes (60 GM, AS, PI3K-Akt signaling pathway, 4 targets, and 56 SMs) and 154 edges. The VEGFA-myricetin, or quercetin, GSK3B-myricetin, IL2-diosgenin complexes formed the most stable conformation, the three ligands were derived from GM. Conversely, NR4A1-vestitol formed stable conformation with the highest affinity, and the vestitol was obtained from AS. The given four SMs were no hurdles to develop into drugs devoid of its toxicity.

conclusionIn conclusion, we show that combinatorial application of AS and GM might be exerted to the potent synergistic effects against NAFLD, dampening PI3K-Akt signaling pathway. This work provides the importance of dietary strategy and beneficial GM on NAFLD, a data mining basis for further explicating the SMs and pharmacological mechanisms of combinatorial application (AS and GM) against NAFLD.

Indexed as

Drugs, Chinese HerbalGastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseAvenaMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor ADrugs, Chinese HerbalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor AAvena sativaGut microbiotaNon-alcoholic fatty liver diseasePI3K-Akt signaling pathwaySecondary metabolitesVEGFA

Identifiers

PMID37069607
PMCPMC10111676
OpenAlexW4366202960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.